HighTower Advisors’s Tema Oncology ETF CANC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.08M Buy
97,197
+20,796
+27% +$879K ﹤0.01% 1381
2026
Q2
$3.15M Buy
76,401
+29,160
+62% +$1.1M ﹤0.01% 1502
2026
Q1
$1.73M Buy
+47,241
New +$1.72M ﹤0.01% 1811

Other funds holding CANC

HighTower Advisors's CANC Position: Q3 2026 in Review

HighTower Advisors increased its Tema Oncology ETF (CANC) stake by 27% in Q3 2026, buying an estimated $879K and bringing the position to 97,197 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

HighTower Advisors first reported a position in CANC in Q1 2026 and has held it in 3 quarters since. 17 funds tracked by Wall St. Rank hold CANC as of Q3 2026.

  • HighTower Advisors held 97,197 shares of Tema Oncology ETF worth $4.08M as of Q3 2026.
  • HighTower Advisors bought 20,796 Tema Oncology ETF shares in Q3 2026, an estimated $879K.
  • Tema Oncology ETF made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #1381 holding.
  • HighTower Advisors first reported a position in Tema Oncology ETF in Q1 2026 and has held it in 3 quarters since.
  • 17 funds tracked by Wall St. Rank held Tema Oncology ETF as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.